Press Center

The new review of the most notable patents disputes in Life Sciences in EAEU and CIS.

• pdf, 13.31 Mb

Lidings takes high positions in the new rating of the leading legal advisors in Russia based on the analytical research held annually by the “Kommersant” newspaper. In 2026 the firm is ranked among the TOP leading legal advisors in Russia. 

April 9^th,2026 annual conference Pharmaceuticals – 2026: Legal Issues will take place in Moscow organized by Pravo.ru. Lidings lawyers take an active part in the event’s program.

As a strategic partner of the conference, we aimed to make the program rich and actual. Together with pharmaceutical industry experts and lawyers, we will discuss how the market has changed in 2025 and what awaits us in 2026.

India has long and firmly established itself as the ‘pharmacy of the world’, as the country produces a fifth of all generics and provides affordable medicines to millions of people across the globe. However, India is now transitioning from copying innovative molecules to creating them. Amid the restructuring of global supply chains and strategic rapprochement with Russia, India is becoming both a battleground for fierce patent wars and a unique laboratory for joint research. How can Russian pharmaceutical companies establish intellectual property protection in a jurisdiction where the balance between the interests of pharmaceutical giants and the affordability of medicines for the population is enshrined in law? Boris Malakhov and Natalya Thotahewage analyse the key features of patenting and the prospects for technological alliances between Moscow and Delhi.

The past days have been marked by landmark rulings from the Russian Supreme and Constitutional Courts, decisions that will influence future case law and the pharmaceutical market as a whole.

On February 17, 2026, the annual flagship seminar of Lidings, "Predictions 2026: Crystal Clarity Instead of Legal Fog," was held at the Hotel Metropol.

The event marked the beginning of a series of celebrations dedicated to the firm's 20th anniversary and brought together over 70 representatives from 50 Russian and international companies.

Lidings' lawyers together with invited speakers from the corporate sector discussed key legislative changes and shared current trends and practical tools.

2026 is a special year for our team — it marks our 20th anniversary. And we are especially pleased to kick it off with a seminar where we will look into the "Crystal of Predictions": back to the past — to review the key legal developments of the past year, and forward to the future — to share crystal-clear insights on the key business trends awaiting in 2026.

On 24 November 2025, the Delhi High Court issued a judgment in a major patent dispute Medilabo Rfp Inc. v. The Controller of Patents C.A. (Comm.Ipd-Pat) 16/2024, concerning the patent eligibility of a drug for neurodegenerative diseases.

In June 2024, the pharmaceutical industry faced a new practice by the Federal Antimonopoly Service (FAS), which began to consistently recognize the introduction of generic drugs onto the market as unfair competition.